aluates Reports

$ 0.0

Automative

Global Immunotherapy for Neuroblastoma Market Research Report 2025

Published Date: May 2025

Report Code: QYRE-Auto-1A14903

Global Immunotherapy for Neuroblastoma Market Research Report 2023

BUY CHAPTERS

Global Immunotherapy for Neuroblastoma Market Research Report 2025

Code: QYRE-Auto-1A14903

Report

May 2025

Pages:72

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

United Therapeutics

Y-mAbs Therapeutics

EUSA Pharma

ANI Pharmaceuticals

Baxter Healthcare

Ingenus Pharmaceuticals

Pfizer Inc

Hikma Pharmaceuticals

Teva Pharmaceuticals

Immunotherapy for Neuroblastoma Market Size

The global market for Immunotherapy for Neuroblastoma was valued at US$ 50 million in the year 2024 and is projected to reach a revised size of US$ 68.2 million by 2031, growing at a CAGR of 4.6% during the forecast period.

Immunotherapy for Neuroblastoma Market

Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient"s age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.

North American market for Immunotherapy for Neuroblastoma is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Immunotherapy for Neuroblastoma is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global market for Immunotherapy for Neuroblastoma in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Immunotherapy for Neuroblastoma include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals, Teva Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Immunotherapy for Neuroblastoma, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immunotherapy for Neuroblastoma.

The Immunotherapy for Neuroblastoma market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Immunotherapy for Neuroblastoma market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Immunotherapy for Neuroblastoma companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Immunotherapy for Neuroblastoma Market Report

Report Metric	Details
Report Name	Immunotherapy for Neuroblastoma Market
Accounted market size in year	US$ 50 million
Forecasted market size in 2031	US$ 68.2 million
CAGR	4.6%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Dinutuximab Naxitamab Other
Segment by Application	Hospital Clinic Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals, Teva Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Immunotherapy for Neuroblastoma company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Immunotherapy for Neuroblastoma Market growing?

Ans: The Immunotherapy for Neuroblastoma Market witnessing a CAGR of 4.6% during the forecast period 2025-2031.

What is the Immunotherapy for Neuroblastoma Market size in 2031?

Ans: The Immunotherapy for Neuroblastoma Market size in 2031 will be US$ 68.2 million.

Who are the main players in the Immunotherapy for Neuroblastoma Market report?

Ans: The main players in the Immunotherapy for Neuroblastoma Market are United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals, Teva Pharmaceuticals

What are the Application segmentation covered in the Immunotherapy for Neuroblastoma Market report?

Ans: The Applications covered in the Immunotherapy for Neuroblastoma Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Immunotherapy for Neuroblastoma Market report?

Ans: The Types covered in the Immunotherapy for Neuroblastoma Market report are Dinutuximab, Naxitamab, Other

Recommended Reports

Pediatric Oncology

Immunotherapy Markets

Cancer Therapies

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Immunotherapy for Neuroblastoma Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Dinutuximab

1.2.3 Naxitamab

1.2.4 Other

1.3 Market by Application

1.3.1 Global Immunotherapy for Neuroblastoma Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Immunotherapy for Neuroblastoma Market Perspective (2020-2031)

2.2 Global Immunotherapy for Neuroblastoma Growth Trends by Region

2.2.1 Global Immunotherapy for Neuroblastoma Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Immunotherapy for Neuroblastoma Historic Market Size by Region (2020-2025)

2.2.3 Immunotherapy for Neuroblastoma Forecasted Market Size by Region (2026-2031)

2.3 Immunotherapy for Neuroblastoma Market Dynamics

2.3.1 Immunotherapy for Neuroblastoma Industry Trends

2.3.2 Immunotherapy for Neuroblastoma Market Drivers

2.3.3 Immunotherapy for Neuroblastoma Market Challenges

2.3.4 Immunotherapy for Neuroblastoma Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Immunotherapy for Neuroblastoma Players by Revenue

3.1.1 Global Top Immunotherapy for Neuroblastoma Players by Revenue (2020-2025)

3.1.2 Global Immunotherapy for Neuroblastoma Revenue Market Share by Players (2020-2025)

3.2 Global Immunotherapy for Neuroblastoma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Immunotherapy for Neuroblastoma Revenue

3.4 Global Immunotherapy for Neuroblastoma Market Concentration Ratio

3.4.1 Global Immunotherapy for Neuroblastoma Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Immunotherapy for Neuroblastoma Revenue in 2024

3.5 Global Key Players of Immunotherapy for Neuroblastoma Head office and Area Served

3.6 Global Key Players of Immunotherapy for Neuroblastoma, Product and Application

3.7 Global Key Players of Immunotherapy for Neuroblastoma, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Immunotherapy for Neuroblastoma Breakdown Data by Type

4.1 Global Immunotherapy for Neuroblastoma Historic Market Size by Type (2020-2025)

4.2 Global Immunotherapy for Neuroblastoma Forecasted Market Size by Type (2026-2031)

5 Immunotherapy for Neuroblastoma Breakdown Data by Application

5.1 Global Immunotherapy for Neuroblastoma Historic Market Size by Application (2020-2025)

5.2 Global Immunotherapy for Neuroblastoma Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Immunotherapy for Neuroblastoma Market Size (2020-2031)

6.2 North America Immunotherapy for Neuroblastoma Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Immunotherapy for Neuroblastoma Market Size by Country (2020-2025)

6.4 North America Immunotherapy for Neuroblastoma Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Immunotherapy for Neuroblastoma Market Size (2020-2031)

7.2 Europe Immunotherapy for Neuroblastoma Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Immunotherapy for Neuroblastoma Market Size by Country (2020-2025)

7.4 Europe Immunotherapy for Neuroblastoma Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Immunotherapy for Neuroblastoma Market Size (2020-2031)

8.2 Asia-Pacific Immunotherapy for Neuroblastoma Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Immunotherapy for Neuroblastoma Market Size by Region (2020-2025)

8.4 Asia-Pacific Immunotherapy for Neuroblastoma Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Immunotherapy for Neuroblastoma Market Size (2020-2031)

9.2 Latin America Immunotherapy for Neuroblastoma Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Immunotherapy for Neuroblastoma Market Size by Country (2020-2025)

9.4 Latin America Immunotherapy for Neuroblastoma Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Immunotherapy for Neuroblastoma Market Size (2020-2031)

10.2 Middle East & Africa Immunotherapy for Neuroblastoma Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Country (2020-2025)

10.4 Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 United Therapeutics

11.1.1 United Therapeutics Company Details

11.1.2 United Therapeutics Business Overview

11.1.3 United Therapeutics Immunotherapy for Neuroblastoma Introduction

11.1.4 United Therapeutics Revenue in Immunotherapy for Neuroblastoma Business (2020-2025)

11.1.5 United Therapeutics Recent Development

11.2 Y-mAbs Therapeutics

11.2.1 Y-mAbs Therapeutics Company Details

11.2.2 Y-mAbs Therapeutics Business Overview

11.2.3 Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Introduction

11.2.4 Y-mAbs Therapeutics Revenue in Immunotherapy for Neuroblastoma Business (2020-2025)

11.2.5 Y-mAbs Therapeutics Recent Development

11.3 EUSA Pharma

11.3.1 EUSA Pharma Company Details

11.3.2 EUSA Pharma Business Overview

11.3.3 EUSA Pharma Immunotherapy for Neuroblastoma Introduction

11.3.4 EUSA Pharma Revenue in Immunotherapy for Neuroblastoma Business (2020-2025)

11.3.5 EUSA Pharma Recent Development

11.4 ANI Pharmaceuticals

11.4.1 ANI Pharmaceuticals Company Details

11.4.2 ANI Pharmaceuticals Business Overview

11.4.3 ANI Pharmaceuticals Immunotherapy for Neuroblastoma Introduction

11.4.4 ANI Pharmaceuticals Revenue in Immunotherapy for Neuroblastoma Business (2020-2025)

11.4.5 ANI Pharmaceuticals Recent Development

11.5 Baxter Healthcare

11.5.1 Baxter Healthcare Company Details

11.5.2 Baxter Healthcare Business Overview

11.5.3 Baxter Healthcare Immunotherapy for Neuroblastoma Introduction

11.5.4 Baxter Healthcare Revenue in Immunotherapy for Neuroblastoma Business (2020-2025)

11.5.5 Baxter Healthcare Recent Development

11.6 Ingenus Pharmaceuticals

11.6.1 Ingenus Pharmaceuticals Company Details

11.6.2 Ingenus Pharmaceuticals Business Overview

11.6.3 Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Introduction

11.6.4 Ingenus Pharmaceuticals Revenue in Immunotherapy for Neuroblastoma Business (2020-2025)

11.6.5 Ingenus Pharmaceuticals Recent Development

11.7 Pfizer

11.7.1 Pfizer Company Details

11.7.2 Pfizer Business Overview

11.7.3 Pfizer Immunotherapy for Neuroblastoma Introduction

11.7.4 Pfizer Revenue in Immunotherapy for Neuroblastoma Business (2020-2025)

11.7.5 Pfizer Recent Development

11.8 Hikma Pharmaceuticals

11.8.1 Hikma Pharmaceuticals Company Details

11.8.2 Hikma Pharmaceuticals Business Overview

11.8.3 Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Introduction

11.8.4 Hikma Pharmaceuticals Revenue in Immunotherapy for Neuroblastoma Business (2020-2025)

11.8.5 Hikma Pharmaceuticals Recent Development

11.9 Teva Pharmaceuticals

11.9.1 Teva Pharmaceuticals Company Details

11.9.2 Teva Pharmaceuticals Business Overview

11.9.3 Teva Pharmaceuticals Immunotherapy for Neuroblastoma Introduction

11.9.4 Teva Pharmaceuticals Revenue in Immunotherapy for Neuroblastoma Business (2020-2025)

11.9.5 Teva Pharmaceuticals Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

United Therapeutics

Y-mAbs Therapeutics

EUSA Pharma

ANI Pharmaceuticals

Baxter Healthcare

Ingenus Pharmaceuticals

Pfizer Inc

Hikma Pharmaceuticals

Teva Pharmaceuticals

List of Tables

Table 1. Global Immunotherapy for Neuroblastoma Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Dinutuximab

Table 3. Key Players of Naxitamab

Table 4. Key Players of Other

Table 5. Global Immunotherapy for Neuroblastoma Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Immunotherapy for Neuroblastoma Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Immunotherapy for Neuroblastoma Market Size by Region (2020-2025) & (US$ Million)

Table 8. Global Immunotherapy for Neuroblastoma Market Share by Region (2020-2025)

Table 9. Global Immunotherapy for Neuroblastoma Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 10. Global Immunotherapy for Neuroblastoma Market Share by Region (2026-2031)

Table 11. Immunotherapy for Neuroblastoma Market Trends

Table 12. Immunotherapy for Neuroblastoma Market Drivers

Table 13. Immunotherapy for Neuroblastoma Market Challenges

Table 14. Immunotherapy for Neuroblastoma Market Restraints

Table 15. Global Immunotherapy for Neuroblastoma Revenue by Players (2020-2025) & (US$ Million)

Table 16. Global Immunotherapy for Neuroblastoma Market Share by Players (2020-2025)

Table 17. Global Top Immunotherapy for Neuroblastoma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immunotherapy for Neuroblastoma as of 2024)

Table 18. Ranking of Global Top Immunotherapy for Neuroblastoma Companies by Revenue (US$ Million) in 2024

Table 19. Global 5 Largest Players Market Share by Immunotherapy for Neuroblastoma Revenue (CR5 and HHI) & (2020-2025)

Table 20. Global Key Players of Immunotherapy for Neuroblastoma, Headquarters and Area Served

Table 21. Global Key Players of Immunotherapy for Neuroblastoma, Product and Application

Table 22. Global Key Players of Immunotherapy for Neuroblastoma, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Immunotherapy for Neuroblastoma Market Size by Type (2020-2025) & (US$ Million)

Table 25. Global Immunotherapy for Neuroblastoma Revenue Market Share by Type (2020-2025)

Table 26. Global Immunotherapy for Neuroblastoma Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 27. Global Immunotherapy for Neuroblastoma Revenue Market Share by Type (2026-2031)

Table 28. Global Immunotherapy for Neuroblastoma Market Size by Application (2020-2025) & (US$ Million)

Table 29. Global Immunotherapy for Neuroblastoma Revenue Market Share by Application (2020-2025)

Table 30. Global Immunotherapy for Neuroblastoma Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 31. Global Immunotherapy for Neuroblastoma Revenue Market Share by Application (2026-2031)

Table 32. North America Immunotherapy for Neuroblastoma Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 33. North America Immunotherapy for Neuroblastoma Market Size by Country (2020-2025) & (US$ Million)

Table 34. North America Immunotherapy for Neuroblastoma Market Size by Country (2026-2031) & (US$ Million)

Table 35. Europe Immunotherapy for Neuroblastoma Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. Europe Immunotherapy for Neuroblastoma Market Size by Country (2020-2025) & (US$ Million)

Table 37. Europe Immunotherapy for Neuroblastoma Market Size by Country (2026-2031) & (US$ Million)

Table 38. Asia-Pacific Immunotherapy for Neuroblastoma Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 39. Asia-Pacific Immunotherapy for Neuroblastoma Market Size by Region (2020-2025) & (US$ Million)

Table 40. Asia-Pacific Immunotherapy for Neuroblastoma Market Size by Region (2026-2031) & (US$ Million)

Table 41. Latin America Immunotherapy for Neuroblastoma Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 42. Latin America Immunotherapy for Neuroblastoma Market Size by Country (2020-2025) & (US$ Million)

Table 43. Latin America Immunotherapy for Neuroblastoma Market Size by Country (2026-2031) & (US$ Million)

Table 44. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Country (2020-2025) & (US$ Million)

Table 46. Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Country (2026-2031) & (US$ Million)

Table 47. United Therapeutics Company Details

Table 48. United Therapeutics Business Overview

Table 49. United Therapeutics Immunotherapy for Neuroblastoma Product

Table 50. United Therapeutics Revenue in Immunotherapy for Neuroblastoma Business (2020-2025) & (US$ Million)

Table 51. United Therapeutics Recent Development

Table 52. Y-mAbs Therapeutics Company Details

Table 53. Y-mAbs Therapeutics Business Overview

Table 54. Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Product

Table 55. Y-mAbs Therapeutics Revenue in Immunotherapy for Neuroblastoma Business (2020-2025) & (US$ Million)

Table 56. Y-mAbs Therapeutics Recent Development

Table 57. EUSA Pharma Company Details

Table 58. EUSA Pharma Business Overview

Table 59. EUSA Pharma Immunotherapy for Neuroblastoma Product

Table 60. EUSA Pharma Revenue in Immunotherapy for Neuroblastoma Business (2020-2025) & (US$ Million)

Table 61. EUSA Pharma Recent Development

Table 62. ANI Pharmaceuticals Company Details

Table 63. ANI Pharmaceuticals Business Overview

Table 64. ANI Pharmaceuticals Immunotherapy for Neuroblastoma Product

Table 65. ANI Pharmaceuticals Revenue in Immunotherapy for Neuroblastoma Business (2020-2025) & (US$ Million)

Table 66. ANI Pharmaceuticals Recent Development

Table 67. Baxter Healthcare Company Details

Table 68. Baxter Healthcare Business Overview

Table 69. Baxter Healthcare Immunotherapy for Neuroblastoma Product

Table 70. Baxter Healthcare Revenue in Immunotherapy for Neuroblastoma Business (2020-2025) & (US$ Million)

Table 71. Baxter Healthcare Recent Development

Table 72. Ingenus Pharmaceuticals Company Details

Table 73. Ingenus Pharmaceuticals Business Overview

Table 74. Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Product

Table 75. Ingenus Pharmaceuticals Revenue in Immunotherapy for Neuroblastoma Business (2020-2025) & (US$ Million)

Table 76. Ingenus Pharmaceuticals Recent Development

Table 77. Pfizer Company Details

Table 78. Pfizer Business Overview

Table 79. Pfizer Immunotherapy for Neuroblastoma Product

Table 80. Pfizer Revenue in Immunotherapy for Neuroblastoma Business (2020-2025) & (US$ Million)

Table 81. Pfizer Recent Development

Table 82. Hikma Pharmaceuticals Company Details

Table 83. Hikma Pharmaceuticals Business Overview

Table 84. Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Product

Table 85. Hikma Pharmaceuticals Revenue in Immunotherapy for Neuroblastoma Business (2020-2025) & (US$ Million)

Table 86. Hikma Pharmaceuticals Recent Development

Table 87. Teva Pharmaceuticals Company Details

Table 88. Teva Pharmaceuticals Business Overview

Table 89. Teva Pharmaceuticals Immunotherapy for Neuroblastoma Product

Table 90. Teva Pharmaceuticals Revenue in Immunotherapy for Neuroblastoma Business (2020-2025) & (US$ Million)

Table 91. Teva Pharmaceuticals Recent Development

Table 92. Research Programs/Design for This Report

Table 93. Key Data Information from Secondary Sources

Table 94. Key Data Information from Primary Sources

Table 95. Authors List of This Report

List of Figures

Figure 1. Immunotherapy for Neuroblastoma Picture

Figure 2. Global Immunotherapy for Neuroblastoma Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Immunotherapy for Neuroblastoma Market Share by Type: 2024 VS 2031

Figure 4. Dinutuximab Features

Figure 5. Naxitamab Features

Figure 6. Other Features

Figure 7. Global Immunotherapy for Neuroblastoma Market Size by Application (2020-2031) & (US$ Million)

Figure 8. Global Immunotherapy for Neuroblastoma Market Share by Application: 2024 VS 2031

Figure 9. Hospital Case Studies

Figure 10. Clinic Case Studies

Figure 11. Other Case Studies

Figure 12. Immunotherapy for Neuroblastoma Report Years Considered

Figure 13. Global Immunotherapy for Neuroblastoma Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 14. Global Immunotherapy for Neuroblastoma Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global Immunotherapy for Neuroblastoma Market Share by Region: 2024 VS 2031

Figure 16. Global Immunotherapy for Neuroblastoma Market Share by Players in 2024

Figure 17. Global Top Immunotherapy for Neuroblastoma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immunotherapy for Neuroblastoma as of 2024)

Figure 18. The Top 10 and 5 Players Market Share by Immunotherapy for Neuroblastoma Revenue in 2024

Figure 19. North America Immunotherapy for Neuroblastoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. North America Immunotherapy for Neuroblastoma Market Share by Country (2020-2031)

Figure 21. United States Immunotherapy for Neuroblastoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Canada Immunotherapy for Neuroblastoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Immunotherapy for Neuroblastoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Immunotherapy for Neuroblastoma Market Share by Country (2020-2031)

Figure 25. Germany Immunotherapy for Neuroblastoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. France Immunotherapy for Neuroblastoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. U.K. Immunotherapy for Neuroblastoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Italy Immunotherapy for Neuroblastoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Russia Immunotherapy for Neuroblastoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Nordic Countries Immunotherapy for Neuroblastoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Immunotherapy for Neuroblastoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Immunotherapy for Neuroblastoma Market Share by Region (2020-2031)

Figure 33. China Immunotherapy for Neuroblastoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Japan Immunotherapy for Neuroblastoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. South Korea Immunotherapy for Neuroblastoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Southeast Asia Immunotherapy for Neuroblastoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. India Immunotherapy for Neuroblastoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Australia Immunotherapy for Neuroblastoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Immunotherapy for Neuroblastoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Immunotherapy for Neuroblastoma Market Share by Country (2020-2031)

Figure 41. Mexico Immunotherapy for Neuroblastoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Brazil Immunotherapy for Neuroblastoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Immunotherapy for Neuroblastoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Immunotherapy for Neuroblastoma Market Share by Country (2020-2031)

Figure 45. Turkey Immunotherapy for Neuroblastoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Saudi Arabia Immunotherapy for Neuroblastoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. UAE Immunotherapy for Neuroblastoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. United Therapeutics Revenue Growth Rate in Immunotherapy for Neuroblastoma Business (2020-2025)

Figure 49. Y-mAbs Therapeutics Revenue Growth Rate in Immunotherapy for Neuroblastoma Business (2020-2025)

Figure 50. EUSA Pharma Revenue Growth Rate in Immunotherapy for Neuroblastoma Business (2020-2025)

Figure 51. ANI Pharmaceuticals Revenue Growth Rate in Immunotherapy for Neuroblastoma Business (2020-2025)

Figure 52. Baxter Healthcare Revenue Growth Rate in Immunotherapy for Neuroblastoma Business (2020-2025)

Figure 53. Ingenus Pharmaceuticals Revenue Growth Rate in Immunotherapy for Neuroblastoma Business (2020-2025)

Figure 54. Pfizer Revenue Growth Rate in Immunotherapy for Neuroblastoma Business (2020-2025)

Figure 55. Hikma Pharmaceuticals Revenue Growth Rate in Immunotherapy for Neuroblastoma Business (2020-2025)

Figure 56. Teva Pharmaceuticals Revenue Growth Rate in Immunotherapy for Neuroblastoma Business (2020-2025)

Figure 57. Bottom-up and Top-down Approaches for This Report

Figure 58. Data Triangulation

Figure 59. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Neuroblastoma Treatment Drugs Market Research Report 2025

Global Neuroblastoma Drugs Market Research Report 2024

Global Neuroblastoma Treatment Market Insights Forecast to 2030

Chemotherapy for Neuroblastoma Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Chemotherapy Drugs for Neuroblastoma Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Neuroblastoma Chemotherapy Drugs Market Research Report 2025

Global Non Rhabdomyosarcoma Treatment Market Research Report 2025

Acute Myeloid Leukemia Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Acute Myeloid Leukemia Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Olfactory Neuroblastoma ONB Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Non Hodgkin Lymphoma Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Intramedullary Osteosarcoma Therapeutics Market Research Report 2024

Global Acute Lymphoid Leukemia Treatment Market Research Report 2024

Pediatric Cardiac Tumor Diagnostic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Non muscle Invasive Bladder Cancer Therapeutics Market Research Report 2025

Paediatric Oncology Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Nephroblastoma Chemotherapy Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Cancer Pain Market Insights Forecast to 2030

Global Intravesical Immunotherapy Market Research Report 2024

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5L19798

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-28I6901

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22R9736

Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-29A2598

Tue Sep 09 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions